| |
| Dabigatran versus warfarin under standard or pharmacogenetic-guided management for the prevention of stroke and systemic thromboembolism in patients with atrial fibrillation: a cost/utility analysis using an analytic decision model |
| Nshimyumukiza L, Duplantie J, Gagnon M, Douville X, Fournier D, Lindsay C, Parent M, Milot A, Giguere Y, Gagne C, Rousseau F, Reinharz D |
|
|
| |
Record Status This is an economic evaluation that meets the criteria for inclusion on NHS EED. Bibliographic details Nshimyumukiza L, Duplantie J, Gagnon M, Douville X, Fournier D, Lindsay C, Parent M, Milot A, Giguere Y, Gagne C, Rousseau F, Reinharz D. Dabigatran versus warfarin under standard or pharmacogenetic-guided management for the prevention of stroke and systemic thromboembolism in patients with atrial fibrillation: a cost/utility analysis using an analytic decision model. Thrombosis Journal 2013; 11(1):14 Indexing Status Subject indexing assigned by CRD MeSH Antithrombins; Atrial Fibrillation; Benzimidazoles; Cost-Benefit Analysis; Genotype; Humans; Markov Chains; Quality-Adjusted Life Years; Stroke; Thromboembolism; Warfarin; beta-Alanine AccessionNumber 22013031530 Date bibliographic record published 23/08/2013 |
| |
|
|
